Investors

Presentations

Title Date Documents

RXi Investor & Analyst Symposium

Clinical Development of RXI-109 to Reduce Dermal Scarring at IBC’s 15th Annual TIDES at the Oligonucleotide and Peptide Therapeutics Conference

Development of sd-rxRNA for Retinoblastoma Therapy at the ARVO Annual Meeting

Update on RXI-109: An RNAi Compound in Clinical Development to Reduce Dermal Scarring at IBC’s 5th Annual AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development

Local Delivery: Lessons Learned from ‘Self-Delivering’ RNAi Compounds at IBC’s 5th Annual AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development

Oligonucleotide-based Therapeutics: 20 Years from Concept to Clinical Validation at the Bio International Convention

Asymmetric, Hydrophobically Modified RNAi Compounds: From Mechanism to Clinical Development at Genomics Research 2012/RNAi and miRNA

Novel RNAi Compounds for Therapeutic Development at 11th Annual EuroTIDES

Evaluation of RNA interference (RNAi) in Skin at the 3rd International SCAR Club Meeting

Chemical and Structural Optimization for Therapeutic Development at AsiaTIDES